论文部分内容阅读
尿激酶(Urokinase)是较链激酶毒性低的血栓溶解药,是唯一提纯的内源性纤溶酶。现报告尿激酶治疗脑血栓形成11例。 临床资料 一般资料 本组男8例,女3例,年龄为24～71岁(平均50岁)。11例均有脑血栓形成的典型症状,脑脊液无血,并经脑血管造影证实。病程为12小时～20天(平均5.8天)。 治疗方法 本组治疗12例次中,以2～3万IU尿激酶作颈内动脉局部注入共2例次,余为静脉滴注,其中尿激酶剂量为2万IU/日者4例次,6万IU/日者6例次,均连用10天。治疗前后及用药期间均测定凝血酶时间、凝血酶元时间、纤维蛋白元、优球蛋白溶解时间、纤溶酶元、纤维蛋白降解产物
Urokinase is a thrombolytic agent that is less toxic than streptokinase and is the only purified endogenous plasmin. It is reported that urokinase treatment of cerebral thrombosis in 11 cases. Clinical data General information The group of 8 males and 3 females, aged 24 to 71 years (mean 50 years). Eleven patients had typical symptoms of cerebral thrombosis, cerebrospinal fluid without blood and confirmed by cerebral angiography. Duration of 12 hours to 20 days (an average of 5.8 days). Treatment of 12 cases of this group were treated with 2 to 30,000 IU urokinase for local injection of carotid artery in a total of 2 cases, more than for intravenous infusion, of which the dose of urokinase 20,000 IU / day in 4 cases, 60,000 IU / day in 6 cases, were used in conjunction for 10 days. Thrombin time, thrombin time, fibrin, euglobulin lysis time, fibrinolytic enzyme, fibrin degradation products